Influenza A virus H7N9 vaccine - Medicago

Drug Profile

Influenza A virus H7N9 vaccine - Medicago

Alternative Names: H7 vaccine; H7 VLP influenza vaccine - Medicago; H7N9 vaccine - Medicago; H7N9 VLP vaccine with GLA adjuvant - Medicago; Plant-based H7N9 VLP vaccine - Medicago; Plant-made H7 virus-like particle influenza vaccine - Medicago

Latest Information Update: 06 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medicago
  • Class Influenza A virus H7N9 vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza A virus H7N9 subtype

Most Recent Events

  • 31 Jul 2015 Phase I development is ongoing Canada
  • 01 Dec 2014 Medicago completes a phase I trial in Influenza-A virus H7N9 subtype (Prevention) in Canada (NCT02022163)
  • 01 Dec 2013 Phase-I clinical trials in Influenza-A virus H7N9 subtype (prevention) in Canada (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top